Retracted: This article has been retracted.

The Effect of Testosterone on Men With Andropause.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 26756004)

Published in Iran Red Crescent Med J on December 26, 2015

Authors

Heshmatollah Sofimajidpour1, Taher Teimoori2, Fardin Gharibi3

Author Affiliations

1: Department of Urology, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, IR Iran.
2: Tohid Hospital, Kurdistan University of Medical Sciences, Sanandaj, IR Iran.
3: Health Management Department, Tohid Haspital, Kurdistan University of Medical Sciences, Sanandaj, IR Iran.

Articles cited by this

Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med (2004) 5.68

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab (1997) 2.71

Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab (1991) 2.27

Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab (1983) 2.20

Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci (2002) 2.12

The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag (2009) 1.90

Androgens in men--uses and abuses. N Engl J Med (1996) 1.66

Testosterone replacement therapy: current trends and future directions. Hum Reprod Update (2004) 1.33

Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab (1984) 1.30

Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol (2012) 1.18

Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab (1984) 1.15

Oral testosterone replacement in symptomatic late-onset hypogonadism: effects on rating scales and general safety in a randomized, placebo-controlled study. Eur J Endocrinol (2009) 1.02

Decreased bioavailable testosterone in aging normal and impotent men. J Clin Endocrinol Metab (1986) 0.98

Androgens: risks and benefits. J Clin Endocrinol Metab (1991) 0.96

An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas (2003) 0.92

Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy (1999) 0.91

Issues in testosterone replacement in older men. J Clin Endocrinol Metab (1998) 0.87

Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: evidence for coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. J Clin Endocrinol Metab (1982) 0.85

Experience with testosterone replacement in the elderly. Mayo Clin Proc (2000) 0.84

Testosterone replacement in men with andropause: an overview. Rev Urol (2004) 0.84

Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea. Asian J Androl (2011) 0.82

Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res (2005) 0.81

Evaluation of transurethral application of alprostadil for erectile dysfunction in Indonesians. Asian J Androl (2000) 0.81

Endocrine aspects of ageing in the male. Mol Cell Endocrinol (1998) 0.81

Androgen replacement therapy improves psychological distress and health-related quality of life in late onset hypogonadism patients in Chinese population. Chin Med J (Engl) (2012) 0.81